Jean-Mathieu Beauregard

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2016-2022
Publications (10 Years): 17

Top Venues

EJNMMI physics

Cancer imaging : the official publication of the International Cancer Imaging Society

European journal of nuclear medicine and molecular imaging

Biomedicines

Université Laval

Université Laval (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Université Laval

Canada

Associate Professor :: Radiology and Nuclear Medicine

CHU de Québec – Université Laval Research Center

Canada

Researcher :: Oncology Division

CHU de Québec – Université Laval

Canada

Nuclear Medicine Physician :: Medical Imaging

Education History

Université Laval

Canada

PHD

Publications

Jean-Mathieu Beauregard
Use of imaging-based dosimetry for personalising radiopharmaceutical therapy of cancer. Cancer imaging : the official publication of the International Cancer Imaging Society 22 (1) (2022)
Alessandro Desy, Guillaume F Bouvet, Nancy Lafrenière, Atefeh Zamanian, Philippe Després, Jean-Mathieu Beauregard
Impact of the dead-time correction method on quantitative 177 Lu-SPECT (QSPECT) and dosimetry during radiopharmaceutical therapy. EJNMMI physics 9 (1) (2022)
Jean-Mathieu Beauregard
Use of imaging-based dosimetry for personalising radiopharmaceutical therapy of cancer. Cancer imaging : the official publication of the International Cancer Imaging Society 22 (1) (2022)
Jean-Mathieu Beauregard
Use of imaging-based dosimetry for personalising radiopharmaceutical therapy of cancer. Cancer imaging : the official publication of the International Cancer Imaging Society 22 (1) (2022)
Jean-Mathieu Beauregard
Use of imaging-based dosimetry for personalising radiopharmaceutical therapy of cancer. Cancer imaging : the official publication of the International Cancer Imaging Society 22 (1) (2022)
Jean-Mathieu Beauregard, Arman Rahmim
Harmonization of nomenclature for molecular imaging metrics of tumour burden: molecular tumour volume (MTV), total lesion activity (TLA) and total lesion fraction (TLF). European journal of nuclear medicine and molecular imaging (2021)
Rashmi G Shah, Marine A Merlin, Samuel Adant, Fayçal Zine-Eddine, Jean-Mathieu Beauregard, Girish M Shah
Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of 177Lu-DOTA-Octreotate in Neuroendocrine Tumor Cells. Cancers 13 (2) (2021)
Andreas Hallqvist, Johanna Svensson, Linn Hagmarker, Ida Marin, Tobias Rydén, Jean-Mathieu Beauregard, Peter Bernhardt
Optimizing the Schedule of PARP Inhibitors in Combination with 177Lu-DOTATATE: A Dosimetry Rationale. Biomedicines 9 (11) (2021)
Alessandro Desy, Guillaume F Bouvet, Étienne Croteau, Nancy Lafrenière, Éric E Turcotte, Philippe Després, Jean-Mathieu Beauregard
Quantitative SPECT (QSPECT) at high count rates with contemporary SPECT/CT systems. EJNMMI physics 8 (1) (2021)
Andrea Frezza, Corentin Desport, Carlos Uribe, Wei Zhao, Anna Celler, Philippe Després, Jean-Mathieu Beauregard
Comprehensive SPECT/CT system characterization and calibration for 177Lu quantitative SPECT (QSPECT) with dead-time correction. EJNMMI physics 7 (1) (2020)
Alessandro Desy, Guillaume F Bouvet, Andrea Frezza, Philippe Després, Jean-Mathieu Beauregard
Impact of dead time on quantitative 177Lu-SPECT (QSPECT) and kidney dosimetry during PRRT. EJNMMI physics 7 (1) (2020)
Salma Meziou, Cassandra Ringuette Goulet, Hélène Hovington, Véronique Lefebvre, Étienne Lavallée, Michelle Bergeron, Hervé Brisson, Audrey Champagne, Bertrand Neveu, Didier Lacombe, Jean-Mathieu Beauregard, François-Alexandre Buteau, Julie Riopel, Frédéric Pouliot
GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcome. Prostate cancer and prostatic diseases 23 (3) (2020)
Samuel Adant, Girish M Shah, Jean-Mathieu Beauregard
Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours. European journal of nuclear medicine and molecular imaging 47 (4) (2019)
Michela Del Prete, François-Alexandre Buteau, Frédéric Arsenault, Nassim Saighi, Louis-Olivier Bouchard, Alexis Beaulieu, Jean-Mathieu Beauregard
Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. European journal of nuclear medicine and molecular imaging 46 (3) (2018)
Michela Del Prete, Frédéric Arsenault, Nassim Saighi, Wei Zhao, François-Alexandre Buteau, Anna Celler, Jean-Mathieu Beauregard
Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT. EJNMMI physics 5 (1) (2018)
Michela Del Prete, François-Alexandre Buteau, Jean-Mathieu Beauregard
Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study. European journal of nuclear medicine and molecular imaging 44 (9) (2017)
Jean-Mathieu Beauregard, Alexis Beaulieu
How we read FCH-PET/CT for prostate cancer. Cancer imaging : the official publication of the International Cancer Imaging Society 16 (1) (2016)

Jean-Mathieu Beauregard.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Jean-Mathieu Beauregard